Esperion Therapeutis.Inc. buy StockNews.com
Start price
15:00
/
50%
€1.97
Target price
05.10.25
-
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 05.10.25. The prediction end date can be changed by StockNews_com at any time.Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Esperion Therapeutis.Inc. | - |
| iShares Core DAX® | -1.114% |
| iShares Nasdaq 100 | 1.816% |
| iShares Nikkei 225® | 2.113% |
| iShares S&P 500 | 2.038% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat